Details of the Drug Reposition

General Information of This Drug (ID: DMB1IU4)

Drug Name
Lenvatinib   DMB1IU4
Synonyms E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Thyroid gland papillary carcinoma DIS48YMM N.A. Approved [1]
Thyroid gland follicular carcinoma DISFK2QT N.A. Approved [1]
Thyroid cancer DIS3VLDH 2D10 Approved [2]
------------------------------------------------------------------------------------
2 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Hepatocellular carcinoma DIS0J828 2C12.02 Phase 3 [3]
Renal cell carcinoma DISQZ2X8 2C90 Phase 3 [4]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Melanoma DIS1RRCY 2C30 Phase 2 [3]
------------------------------------------------------------------------------------
1 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1/2 [4]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Ovarian cancer DISZJHAP 2C73 Phase 1 [5]
------------------------------------------------------------------------------------
1 Application submitted Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-small-cell lung cancer DIS5Y6R9 2C25.Y Application submitted [4]
------------------------------------------------------------------------------------

References

1 Lenvatinib FDA Label
2 FDA Approved Drug Products from FDA Official Website. 2018. Application Number: (ANDA) 208627.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.